GefitinibDiarrhoea and acquired drug resistance: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1731卷 / 1期

关键词：

D O I：

10.1007/s40278-018-55319-3

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：124 / 124

相关论文

共 50 条

[41] GefitinibDevelopment of acquired resistance: case report
Reactions Weekly, 2017, 1680 (1) : 151 - 151
[42] InfliximabDevelopment of acquired resistance: case report
Reactions Weekly, 2023, 1939 (1) : 250 - 250
[43] GefitinibDevelopment of acquired resistance: case report
Reactions Weekly, 2018, 1703 (1) : 120 - 120
[44] Ceritinib/crizotinibDevelopment of acquired resistance: case report
Reactions Weekly, 2020, 1813 (1) : 75 - 75
[45] Avibactam/ceftazidimeEmergence of acquired resistance: case report
Reactions Weekly, 2022, 1913 (1) : 90 - 90
[46] OsimertinibRash, diarrhoea and acquired resistance: case report
Reactions Weekly, 2020, 1813 (1) : 184 - 184
[47] AntineoplasticsTreatment failure and acquired resistance: case report
Reactions Weekly, 2022, 1937 (1) : 68 - 68
[48] AntineoplasticsLack of efficacy and acquired resistance: case report
Reactions Weekly, 2022, 1919 (1) : 68 - 68
[49] Gefitinib/osimertinibHepatotoxicity and acquired resistance: case report
Reactions Weekly, 2022, 1923 (1) : 232 - 232
[50] AntineoplasticsLack of efficacy and acquired resistance: case report
Reactions Weekly, 2023, 1955 (1) : 40 - 40

← 1 2 3 4 5 →